Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, Xu J, Zhang H, Chen J, Yuan Y, Liu T, Yang L, Zhong H, Chen D, Shen L, Hao C, Fu D, Cheng Y, Yang J, Wang Q, Qin B, Pan H, Zhang J, Bai X, Zheng Q. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal Of Clinical Oncology 2023, 41: 5163-5173. PMID: 37647576, PMCID: PMC10666986, DOI: 10.1200/jco.22.02630.Peer-Reviewed Original ResearchConceptsProgression-free survivalK-ras wild-type tumorMetastatic pancreatic cancerWild-type tumorsOverall survivalPancreatic cancerK-rasMedian progression-free survivalProgression-free survival timePhase III clinical studiesK-ras wild-typeResponse rateIncidence of adverse eventsDisease control rateSecondary end pointsIII clinical studiesPhase IIb trialMean survival timeMedian OSNimotuzumab groupImproved OSPlacebo groupClinical benefitSafety profileAdverse events